General Information of Drug (ID: DMN43Q5)

Drug Name
Peptide analog 70 Drug Info
Synonyms PMID26118988-Compound-9
Cross-matching ID
TTD Drug ID
DMN43Q5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug(s) Targeting Neutrophil elastase (NE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sivelestat sodium hydrate DMOSJD0 Acute lung injury NB32.3 Phase 4 [2]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [3]
Sivelestat DM6BZCV Crohn disease DD70 Phase 3 [4]
Tiprelestat DM1SB94 Myocardial infarction BA41-BA43 Phase 2 [5]
AZD9668 DMB87M3 Bronchiectasis CA24 Phase 2 [6]
L-694,458 DMA0DSJ Cystic fibrosis CA25 Phase 2 [7]
BAY 85-8501 DMCPUKG Bronchiectasis CA24 Phase 2 [8]
DX-890 DMBFZET Acute lung injury NB32.3 Phase 2 [2]
POL-6014 DM9B68S Cystic fibrosis CA25 Phase 1 [9]
AZD-9819 DMWYHXG Chronic obstructive pulmonary disease CA22 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin G (CTSG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
JNJ-10311795 DM7OTQS Chronic obstructive pulmonary disease CA22 Phase 2 [11]
Peptide analog 59 DMZAMNX N. A. N. A. Patented [1]
Peptide analog 61 DM45JMT N. A. N. A. Patented [1]
Peptide analog 55 DMVLP8H N. A. N. A. Patented [1]
Peptide analog 60 DMMSTNA N. A. N. A. Patented [1]
Peptide analog 56 DMBCFJU N. A. N. A. Patented [1]
Peptide analog 57 DM6IQWE N. A. N. A. Patented [1]
Peptide analog 58 DM7X62M N. A. N. A. Patented [1]
Peptide analog 62 DM28NK0 N. A. N. A. Patented [1]
Aloxistatin DMGW07M Neurological disorder 6B60 Discontinued in Phase 3 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin G (CTSG) TTQAJF1 CATG_HUMAN Inhibitor [1]
Neutrophil elastase (NE) TTPLTSQ ELNE_HUMAN Inhibitor [1]

References

1 Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58.
2 Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
3 Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5.
4 Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
5 Company report (Proteo Biotech AG)
6 Clinical pipeline report, company report or official report of AstraZeneca (2009).
7 Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
8 Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
10 Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9.
11 Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
12 Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem. 2007 Jul 20;282(29):20836-46.